

September 6, 2017
Hugstetterstr. 55
79106 Freiburg
Germany

PATIENT CONSENT FOR PUBLICATION

I hereby give my consent for all or any part of my clinical information, including images relating to my case, to be reported in a medical publication.

I understand that my name and initials will not be published and that efforts will be made to conceal my identity.

Ulrike Söder-Suerbier
(Patient)

Ulrike Söder-Suerbier Sept. 6, 17

Prof. Dr. Wolfgang Kreisel
(Attending Physician)

Wolfgang Kreisel Sept 6, 17



UNIVERSITÄTS
KLINIKUM FREIBURG

Department Innere Medizin

Institut für Bewegungs-
und Arbeitsmedizin

Ärztlicher Leiter
Prof. Dr. med. Peter Deibert

Telefon 0761 270-74600
Telefax 0761 270-74700
ibam@uniklinik-freiburg.de

INFORMED CONSENT

My signature below indicates that I have decided to volunteer as a research participant for the study *Therapy of Cirrhotic Portal Hypertension with Inhibitors of PDE-5* and that I have been informed about the study objectives, benefits, risks, and possible side effects of the medications. I have been made aware that the Inhibitors of PDE-5 (i.e. Vardenafil and Tadalafil) are not approved medications for portal hypertension in Germany. The clinical intervention started in February 2009 with appropriate and sufficient consultation with the investigators of the study.

Subject's Name (print):

Ulrike Söder-Suerbier

Subject's Signature:

U. Söder-Suerbier

Date:

17.11.2017

Investigator's Signature:

Peter Deibert

Date:

22.11.2017